CRISPR gene editing

CRISPR gene editing
Deposition authors: Nishimasu, H., Ishitani, R., Nureki, O.; Visualization autho · CC0 · source
Name	CRISPR gene editing
Discovery	1987
Inventors	Emmanuelle Charpentier, Jennifer Doudna
Field	Molecular biology, Biotechnology
Organisms	Bacteria, Archaea, Eukaryotes

Contents

CRISPR gene editing is a genome modification technique derived from adaptive immune systems discovered in prokaryotes that enables targeted alteration of DNA sequences using RNA-guided nucleases. Developed into a versatile toolkit by researchers across institutions such as the University of California, Berkeley, the Max Planck Society, and the Broad Institute, it rapidly influenced research at laboratories like the Howard Hughes Medical Institute and companies including Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics. Major recognition for foundational work was reflected in awards including the Nobel Prize in Chemistry.

History

Origins trace to sequence patterns identified by researchers at Osaka University, International Congress of Microbiology, and the laboratory of Francisco Mojica at the University of Alicante, where repetitive elements were first described and linked to phage resistance. Key milestones include characterization of CRISPR loci by teams at Erasmus University Rotterdam and mechanistic insights from investigations at Institut Pasteur and Rockefeller University. The adaptation of CRISPR systems for programmable editing emerged from collaboration between groups at University of Vienna, University of California, San Francisco, and laboratories led by Emmanuelle Charpentier and Jennifer Doudna, followed by competitive patent disputes adjudicated in venues involving the United States Patent and Trademark Office and courts connected to Massachusetts Institute of Technology. Early clinical translation engaged research from centers like National Institutes of Health, Mayo Clinic, and partnerships with biotechnology firms such as Sangamo Therapeutics and Novartis.

The system functions through recognition modules and effector nucleases exemplified by proteins characterized at the Max Planck Institute for Infection Biology and crystallized by teams at University of Zurich and Harvard University. Guide RNAs designed in silico using algorithms from groups at Stanford University, Massachusetts Institute of Technology, and University of Cambridge target sequences adjacent to protospacer adjacent motifs defined by studies at Cold Spring Harbor Laboratory. DNA cleavage by nucleases discovered in different lineages, including variants related to research at Sanger Institute and California Institute of Technology, initiates repair pathways such as non-homologous end joining explored at Johns Hopkins University and homology-directed repair investigated at University of Oxford. Engineered versions, including base editors and prime editors developed at Broad Institute and University of Tokyo, modulate activity, while delivery methods adapted from work at Eli Lilly and Company, AstraZeneca, and Gilead Sciences use viral vectors, lipid nanoparticles, or electroporation optimized in core facilities at Wellcome Trust research centers.

Research and therapeutic applications span laboratories at Memorial Sloan Kettering Cancer Center, clinics affiliated with Cleveland Clinic, and agricultural programs at International Rice Research Institute. Clinical trials for hematologic and metabolic disorders initiated by teams at University of Pennsylvania and companies such as Vertex Pharmaceuticals explore ex vivo editing of hematopoietic stem cells, while in vivo studies led by collaborators at Johns Hopkins University and University College London target ocular and hepatic diseases. Agricultural editing projects at Iowa State University, Wageningen University, and Chinese Academy of Sciences aim to improve traits in crops like rice and maize, influenced by collaborations with Bayer and Syngenta. Conservation efforts involving institutions such as Smithsonian Institution and Conservation International have investigated gene drive concepts first modeled at Imperial College London and Michigan State University for vector control of organisms studied in Centers for Disease Control and Prevention programs. Industrial biotechnology implementations draw on process development at DuPont and Genentech.

Debates spanning meetings organized by World Health Organization, panels convened by National Academies of Sciences, Engineering, and Medicine, and hearings before bodies like the United States Congress highlight concerns over germline modification and equitable access raised by ethicists affiliated with Harvard Medical School, Georgetown University, and Yale University. International regulatory variation appears between frameworks implemented by the European Commission, the Food and Drug Administration, and regulatory authorities in China and Japan, reflecting recommendations from committees at World Economic Forum summits and position statements from organizations such as Amnesty International and Doctors Without Borders. High-profile controversies involving labs at Sun Yat-sen University and policy responses from institutions including Wellcome Trust prompted calls for moratoria and governance strategies debated at forums hosted by United Nations Educational, Scientific and Cultural Organization.

Technical limitations documented by teams at Broad Institute, Sanger Institute, and Beth Israel Deaconess Medical Center include off-target effects characterized using deep sequencing methods developed at European Bioinformatics Institute and error-prone repair outcomes described in studies from Cold Spring Harbor Laboratory. Delivery hurdles constrain translation despite advances from engineering groups at Massachusetts Institute of Technology and University of California, San Diego using viral, non-viral, and nanoparticle systems refined in collaboration with Samsung Biologics and Moderna. Immunogenicity concerns tied to prior exposure to nuclease homologs studied at UCSF Medical Center and escape mutations observed in pathogen research at Pasteur Institute complicate durable efficacy, while scalability and manufacturing challenges affect commercialization efforts undertaken by Pfizer and contract manufacturers associated with Catalent. Ongoing research at centers like ETH Zurich and Karolinska Institute seeks to address specificity, efficiency, and biosafety through iterative engineering and multidisciplinary consortia.

Category:Genetic engineering